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Background: To investigate the clinicopathological features of surgically resected pancreatic cystic neoplasms
(PCNs) at a single institution in China.
Methods: The medical charts of patients who operated in the Second Affiliated Hospital, Zhejiang University
School of Medicine between 1 January 1997 and 30 June 2013, were pathologically shown to have PCNs.
Results: There was a reliable increase trend not just in the overall number of patients (3 to 75) but additionally in
the number of incidentally diagnosed patients across the periods (33.3% to 48.0%). In 83 of 111 cases, preoperative
diagnoses matched with pathology, whereas the remaining cases (16/28) were misdiagnosed as pancreatic cancer.
The proportion of malignancy in mucin producing neoplasms was 24.3% (9 out of 37). Elevated serum
carbohydrate antigen (CA19-9) or carcinoembryonic antigen (CEA) was independently associated with malignancy.
The overall survival rate was 96.4%.
Conclusions: The proportion of PCNs within this series differs with that revealed in Western countries. Appropriate
preoperative differential diagnosing of PCNs remains challenging. It is strongly recommended that patients with
elevated CA19-9 or CEA levels undergo surgical resection.
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The widespread use of abdominal imaging in China in
the past decade has resulted in a dramatic increase in
the identification of pancreatic cystic neoplasms (PCNs).
This is similar to Western series such as the United
States, in which cross sectional imaging has been used
extensively for a longer period of time. In the Western
series it has been reported that 2.6% of patients under-
going an abdominal CT scan are found to have a cystic
neoplasm and another study reports 13% of patients
undergoing abdominal MRI scans have cystic neoplasms* Correspondence: liangtingbo@zju.edu.cn
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unless otherwise stated.[1-4]. The incidence of pancreatic cystic lesions is about
1 in 100 hospitalized patients in the United States [5].
PCN exists as a spectrum of diseases that range from
completely benign to frankly malignant. Thus, careful
selection for operative intervention is necessary for opti-
mal outcomes in the management of patients with PCN.
Currently, guidelines exist that guide selection for resec-
tion and are followed by most experienced centers [6].
These criteria are based on clinical features, imaging
characteristics, and findings on endoscopic ultrasound/
fine needle aspiration (EUS/FNA).
To date very few Chinese studies concerning surgical
treatment of PCNs have been reported. It is likely that
based on differences in genetic backgrounds, risk factors,
and use of cross sectional imaging, significant difference
exists in the incidence and indications for resection ofThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Distribution of PCNs in 111 patients.
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the goal of this study is to report the experience of
patients undergoing resection of a PCN at a single
university-based high-volume pancreatic surgery center
in China. In this study, we retrospectively reviewed and
analyzed the data for 111 patients who underwent oper-
ations and were pathologically confirmed to have four
major types of PCNs: intraductal papillary mucinous
neoplasm (IPMN), mucinous cystic neoplasm (MCN),
serous cystic neoplasm (SCN), and solid pseudopapillary
neoplasm (SPN). To our knowledge, this is the largest
series of surgically resected PCNs reported in English
from China to date.
Methods
This study was approved by the Ethics Committee of the
Second Affiliated Hospital, School of Medicine, Zhejiang
University and was performed according to the Declar-
ation of Helsinki [7]. Records of patients who underwent
surgical resection and were pathologically proven to
have IPMN, MSC, SCN, or SPN between 1 January
1997, and 30 June 2013 at the Second Affiliated Hospital
of Zhejiang University School of Medicine (China) were
retrospectively reviewed and analyzed. The preoperative
diagnosis, which was based on clinical manifestations,
serum tumor markers, and the results of imaging includ-
ing computed tomography (CT), magnetic resonance
imaging (MRI) or magnetic resonance cholangiopancrea-
tography (MRCP), were compared with the postopera-
tive pathological diagnosis.
A serum carbohydrate antigen 199 (CA19-9) level of
more than 37 U/L and a carcinoembryonic antigen
(CEA) level of more than 5 ng/mL were considered to
be elevated. Pancreatic fistula was diagnosed according
to the International Study Group on Pancreatic Fistula
criteria [8].
In the final pathologic reports, cystic neoplasms were
classified according to the World Health Organization
classification of the exocrine and endocrine neoplasms
of the pancreas [9]. IPMN and MCN were graded based
on degree of dysplasia: low-grade, intermediate grade,
high-grade (carcinoma in situ (CIS)), and invasive. Ser-
ous cystadenocarcinoma was defined by the presence of
metastases [10].
Information about recurrence and survival time was
obtained via follow-up phone calls and clinical inter-
views. Statistical analysis was carried out using SPSS
version 19.0 (SPSS, Chicago, Illinois, United States).
Continuous variables were expressed as medians and
ranges and compared using the Mann-Whitney test.
Categorical variables were compared using a chi-squared
test (or Fisher’s exact test). Univariate analyses were con-
ducted using chi-square or Mann-Whitney U tests, as
appropriate, and multivariate analysis was performedusing forward step-wise logistic regression analysis. Sur-
vival analysis was performed using the Kaplan-Meier
method, with differences determined by the log-rank
test. All tests were two-sided and P <0.05 was consid-
ered to indicate statistical significance.
Results
Demographic data and clinical features
A total of 111 patients were enrolled in this study, in-
cluding 17 (15.3%) with IPMNs, 20 (18.0%) with MCNs,
39 (35.1%) with SCNs, and 35 (31.5%) with SPNs
(Figure 1). All patients were of Chinese ethnicity. The
age of the patients varied from 13 to 81 years, with the
median age of 46 years, and 75.7% were female (Table 1).
Patients undergoing resection of SPN (median age: 30
years; range: 13 to 59 years) were significantly younger
than those in the IPMN group (median age: 71 years;
range: 44 to 81 years; P <0.001), MCN group (median
age: 48 years; range: 24 to 75 years; P <0.001) and SCN
group (median age: 53 years; range: 24 to 78 years;
P <0.001). Meanwhile, the patients with IPMN (median
age: 71 years; range: 44 to 81 years) were older than the
other patients (P <0.001). Females were more common
among SPN (91.4%, 32 out of 35), MCN (100%, 20 out of
20) and SCN (71.8%, 28 out of 39), while IPMN noted a
slight male dominance (76.5%, 13 out of 17; P <0.05).
Sixty-two (55.9%) patients presented symptoms at admis-
sion. Of these, the chief complaint was abdominal pain
and distention in 50 patients (45.0%) and weight loss in 9
(8.1%) patients; jaundice, nausea, and tumor on palpation
were found in 19 cases (17.1%). There was no significant
difference among the various PCNs. Forty-nine patients
(44.1%) were asymptomatic, and their cysts had been
Table 1 Clinical data for the 111 pancreatic cystic neoplasms
IPMN (n = 17) MCN (n = 20) SCN (n = 39) SPN (n = 35)
Age, years, median (range) 71 (44-81) 48 (24-75) 53 (24-78) 30 (13-59)
Gender, n (%)
Male 13 (76.5%) 0 (0%) 11 (28.2%) 3 (8.5%)
Female 4 (23.5%) 20 (100%) 28 (71.8%) 32 (91.4%)
Symptoms, n (%) 13 (76.5%) 12 (60%) 21 (53.8%) 16 (45.7%)
Abdominal pain and distension 9 8 18 15
Weight loss 3 2 3 1
Jaundice 2 0 1 0
Nausea 1 1 2 5
Tumor palpation 1 4 1 1
No symptoms, n (%) 4 (23.5%) 8 (40%) 18 (46.2%) 19 (54.3%)
Tumor location, n (%)
Head and/or uncinate process 12 (70.6%) 1 (5.0%) 16 (41.0%) 14 (40.0%)
Neck 2 (11.8%) 1 (5.0%) 6 (15.4%) 3 (8.6%)
Body and/or tail 3 (17.6%) 18 (90.0%) 17 (43.6%) 18 (51.4%)
Tumor size, cm, median (range)
Length 3.4 (1.8-15.0) 6.0 (2.8-18.0) 4.5 (1.2-15.0) 4.0 (1.2-15.0)
Width 2.6 (1.0-10.0) 5.0 (2.0-10.0) 3.0 (1.2-10.0) 3.5 (1.2-8.0)
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ation or on imaging performed for another complaint.
The majority of MCNs (90.0%, 18 out of 20) occurred in
the body and tail of the pancreas, whereas SCNs and SPNs
tended to be evenly distributed. IPMNs (70.6%, 12 out of
17) were far more likely to be located in the head. MCNs
were significantly larger compared with other cystic neo-
plasms, with a median length of 6.0 cm (range: 2.8 to
18.0 cm; P <0.05) and width of 5.0 cm (range: 2.0 to
10.0 cm; P <0.05).
Trends in the incidence and types of PCNs
In our study, patient characteristics were analyzed and
compared among four periods (Table 2) from 1997 to
2013: 1997 to 2000, 2001 to 2004, 2005 to 2008, and






Time interval, months, median (range)* 0.3 (0.2-12.0)
Pancreatic cystic neoplasms, n (%)
IPMN (intraductal papillary mucinous neoplasm) 0
MCN (mucinous cystic neoplasm) 2 (66.7%)
SCN (serous cystic neoplasm) 1 (33.3%)
SPN (solid pseudopapillary neoplasm) 0
*The time lapse from the presentation of symptoms and diagnosis of the cystic lesithe total number of patients but also in the number of
incidentally diagnosed patients. The number of patients
who were incidentally diagnosed in the last four years
(2009 to 2013) was 36, which is a three-fold increase
compared to the 2005 to 2008 period. In the same
period (2009 to 2013), almost one-half of the resected
PCNs were found incidentally, although it did not reach
a significant difference. The median time lapse from the
presentation of symptoms and diagnosis of the cystic le-
sions of the pancreas was one month (range: 0.02 to
144), no significant difference was found between these
time periods.
Additionally, the proportion of the pathological types
of PCNs varied with time. During 2009 to 2013, SPN and
SCN each comprised 36.0% and 29.3% of PCNs; however,
in 2005 to 2008 SCN was the main pathological type,sms
2001-2004 2005-2008 2009-2013
6 (5.4%) 27 (24.3%) 75 (67.6%)
4 (66.7%) 17 (63.0%) 39 (52.0%)
2 (33.3%) 10 (37.0%) 36 (48.0%)
1 (0.2-48.0) 1 (0.1-120.0) 1 (0.02-144.0)
0 5 (18.5%) 12 (16.0%)
1 (16.7%) 3 (11.1%) 14 (18.7%)
1 (16.7%) 15 (55.6%) 22 (29.3%)
4 (66.7%) 4 (14.8%) 27 (36.0%)
ons of the pancreas.
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accounted for 14.8% of PCNs (P <0.05). IPMNs also
showed an increasing trend over time: only 5 patients
were diagnosed before 2008, while it was confirmed in 12
patients in 2009 to 2013, although it did not reach a statis-
tically significant difference.
Preoperative diagnostic accuracy
In the preoperative work-up, an abdominal CT scan was
performed in 104 of 111 patients (93.7%), and an MRI
or MRCP was used in 27 (24.3%) patients. In addition,
EUS/FNA and endoscopic retrograde cholangiopancreato-
graphy (ERCP) were performed in 2 (1.8%) and 1 (0.9%)
patients, respectively.
Preoperative diagnoses of 83 patients were approved
by pathology, while the remaining 21 (18.9%, 21/111)
were misdiagnosed as pancreatic cancer (in 16 patients),
pseudocyst (in 4 patients) and neuroendocrine tumor (in
1 patient). Seven (6.3%, 7/111) patients were indistin-
guishable from other PCNs (Table 3).
Surgical intervention and operative complications
A surgical intervention was performed because of the
presence of symptoms in 62 patients. In the other 49
(44.1%) asymptomatic patients, resection was driven by
the suspected malignancy or uncertain diagnosis with
tumor size of larger than 3 cm.
In 39 SCNs, 21 patents (53.8%) were operated on be-
cause of clinical symptoms and 11 were operated on be-
cause of large tumors (more than 4 cm) [11]. Four
patients were misdiagnosed as pancreatic cancer, and 3
patients’ tumors were indistinguishable from MCNs be-
fore the operation.
In total, 50 (45.0%) distal pancreatectomies (of which
14 procedures were done with preservation of the spleen
and 4 were performed laparoscopically), 26 (23.4%) pan-
creaticoduodenectomies, 17 (15.3%) middle pancreatecto-
mies, 15 (13.5%) enucleations, 1 (0.9%) pylorus-preserving
pancreaticoduodenectomy, 1 (0.9%) total pancreatectomy,
and 1 (0.9%) laparotomy with a diagnostic biopsy were
performed (Table 4).
Postsurgical complications occurred in 50 patients
(45.0%), among whom the most common complication
was pancreatic fistula (29.7%, 33 out of 111). The incidenceTable 3 Preoperative diagnosis of pancreatic cystic neoplasm
IPMN (n = 17)
Preoperative diagnosis, n, (%) 11 (64.7%)




Others PCNsof pancreatic fistula was higher in the SPN group (42.9%,
15 out of 35), but was not significantly different between
the other groups (P >0.05). Other complications included
intra-abdominal infection (14.4%, 16 out of 111), pleural
effusion (11.7%, 13 out of 111), delayed gastric emptying
(8.1%, 9 out of 111), pulmonary infection (6.3%, 7 out of
111), bile leakage (3.6%, 4 out of 111) and wound infection
(2.7%, 3 out of 111). Furthermore, reoperation was neces-
sary in 4 patients (3.6%, 4 out of 111); 2 due to hemor-
rhages, 1 due to bile leakage, and 1 due to pancreatic
fistula. The mortality rate in this series was 0.9% (1 out of
111): one patient in the IPMN group who underwent dis-
tal pancreatectomy died on the 22nd postoperative day
because of pneumonia and septic shock. The median hos-
pital stay after surgery was 17.0 days (range: 7 to 123 days)
in 110 patients. In the MCN group, this was 13.0 days
(range: 8.0 to 26.0 days), which was significantly shorter
than that in the IPMN group (median: 19.0 days; range:
12.0 to 74.0 days; P <0.05), SCN group (median: 20.0 days;
range: 7.0 to 123.0 days; P <0.05) and SPN group (median:
16.0 days; range: 7.0 to 99.0 days; P <0.05).
Predictive factors of malignancy in mucin-producing
neoplasms
In mucin-producing neoplasms (IPMNs and MCNs),
malignancy was found 9 patients, 6 in IPMNs, and 3 in
MCNs. Univariate analysis revealed gender and elevated
CA19-9 or CEA level to be significant predictive factors
of malignance (Table 5). Multivariate analysis revealed
that elevated CA19-9 or CEA levels were independent
predictive factors of malignancy (P <0.05) (Table 6).
Follow-up data
Survival data were collected from all 110 patients, who
were followed-up for a median time of 35.67 months (0.9
to 188.23 months). The overall survival rate was 96.4%.
Survival analysis showed that the survival rate of SPNs
(100%) and SCNs (100%) was significantly better than that
of IPMNs (87.5%) and MCNs (90.0%) (Figure 2).
Discussion
In this study we have obtained comprehensive data on the
trends in PCNs in one single institution in China over the
last 16 years. We found an increase in the number ofs
MCN (n = 20) SCN (n = 39) SPN (n = 35)
17 (85%) 28 (71.8%) 27 (77.1%)
3 (15%) 11 (28.2%) 8 (22.9%)
4 (36.5%) 7 (87.5%)
1 (9%)
3 (100%)
6 (54.5%) 1 (12.5%)
Table 4 Surgical interventions and morbidity
IPMN (n = 17) MCN (n = 20) SCN (n = 39) SPN (n = 35)
Types of resection, n (%)
Distal pancreatectomy, splenectomy 2 (11.8%) 11 (55%) 11 (28.2%) 12 (34.3%)
Spleen-preserving distal pancreatectomy 2 (11.8%) 6 (30%) 3 (7.7%) 3 (8.6%)
Pancreaticoduodenectomy 11 (64.7%) 6 (15.4%) 9 (25.7%)
Pylorus-preserving pancreaticoduodenectomy 1 (2.6%)
Middle pancreatectomy 12 (30.8%) 5 (14.3%)
Tumor enucleation 1 (5.9%) 2 (10%) 6 (15.4%) 6 (17.1%)
Laparotomy with biopsy 1 (5%)
Total pancreatectomy 1 (5.9%)
Postoperative complications, n (%) 8 (47.1%) 6 (30%) 15 (38.5%) 21 (60%)
No complications, n (%) 9 (52.9%) 14 (70%) 24 (61.5%) 14 (40%)
Re-operation (n) 0 0 2 (5.1%) 2 (5.7%)
Hospital stay after surgery, days, median (range) 19.0 (12.0-74.0) 13.0 (8.0-26.0) 20.0 (7.0-123.0) 16.0 (7.0-99.0)
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is similar to the data for other countries. For example,
PCNs were found to represent at least 25% of resections
at the major pancreatic referral centers in the United
States in 2003 [12].
A detailed review of previous studies has shown that
there is a difference in the relative proportions ofTable 5 Univariate analysis of predictive factors of













Tumor location (n) 0.573
Head and/or uncinate process 4 8
Neck 1 2





MCN (mucinous cystic neoplasm) 3 17
Elevated serum carbohydrate





Tumor size (cm) 0.403
>3 cm 8 20
≤3 cm 1 8different pathologic diagnoses. Coelho et al. [13] re-
ported in 2010 that only 4 (15%) patients were diagnosed
IPMN, and in a series of 599 consecutive patients, Bassi
et al. [14] found an IPMN rate of 17%. In our study,
IPMN was only diagnosed in 15.3% of the patients. In
contrast to this, a recent study at Massachusetts General
Hospital demonstrated that IPMN was the most com-
mon type of PCN resected and accounted for nearly
one-half of the resected cystic neoplasms in the last five
years [15]. Main duct and/or mixed-duct and branch-
duct IPMN were also reported to comprise 48.6% of
PCNs in the Department of Surgery, University of
Verona, Italy, in 2012 [16]. This disagreement between
the results may be explained by the following: (1) Due to
economic issues, abdominal cross-sectional imaging
examination with CT or MRI is not routinely performed
in China so far. While most IPMNs are asymptomatic,
this may lead to a low detection rate of IPMN. (2) The
recognition of IPMN by a pathologist in China is prob-
ably not as good as in Western countries. Under these
circumstances, IPMN may be misdiagnosed as MCN or
pancreatic adenocarcinoma. According to a recent publi-
cation on 2564 resected periampullary adenocarcinomas
at Johns Hopkins’s hospital, the frequency of pancreatic
cancer arising from IPMN was 8% during the 2000s [17].
We cannot exclude the possibility that pancreatic cancersTable 6 Multivariate analysis of the predictive factors of











Figure 2 Kaplan-Meier overall survival curves of patients who
underwent surgical operations for pancreatic cystic neoplasms.
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as cancer while neglecting theirIPMN origin, which may
also attribute to the low frequency of IPMN in our series.
(3) To date, there are very few publications on PCN from
China and the real proportion of each type in China is
still unknown. Whether there is a racial difference-related
proportion is need to be further investigated. The accur-
acy of preoperative diagnosis of IPMN was 64.7% at our
hospital during our 16-year experience, whereas the rate
of correct diagnosis for IPMN was 80% in the series in
Salvia et al. [16].
IPMN was first differentiated from mucin-producing
cystic neoplasms by Ohashi and Murakami in 1990 [18];
before this, the detection rate of IPMNs was only 3% [19].
It has been established that MCNs do not generally com-
municate with the pancreatic ducts, a macroscopic feature
used in many series as a factor to determine MCN from
IPMN [19]. The sole criterion for the diagnosis of MCN is
the presence of well-demarcated cysts lined by a mucin-
producing columnar epithelium overlying an ovarian-type
stroma. Therefore, some authors re-evaluated pathology
slides from previous reports. Niedergethmann et al. [20]
reported in 2008 that the incidence of incorrect diagnosis
was greater in the earlier time period (1996 to 2001) of
their study, so they eventually reclassified 54 neoplasms as
IPMN among 207 cases, which was 125% more than the
originally diagnosed number. In another study, Tollefson
et al. [21] also found that 21 cases of IPMN were misdiag-
nosed among 84 cases between 1960 and 1980 at the
Mayo Clinic (Rochester, Minnesota).
The incidence of SPN reported here is also quite dif-
ferent from that in other reports. SPN is a rare tumor; itforms 1 to 3% of all pancreatic tumors and 5% of all cys-
tic tumors of the pancreas according to previous results
[22]. This results concur with those of Valsangkar et al.’s
analysis [14] in which only 29 (3.4%) of the patients were
diagnosed with an SPN. The data from another retro-
spective study of 476 patients who underwent pancreatic
resection also documented a lower incidence (8.0%) in
2012 [16]. Similarly, Bassi et al. [14] reported that the
incidence of SPN was 6.5%. On the contrary, a higher
prevalence of SPN (31.5%, 35 out of 111) was found in
our series, with 77.1% of the patients diagnosed in 2009
to 2013. There also has been a higher incidence in the
number of SPNs reported in another case series in China
(17.3%) in 2005 [23]. Furthermore, a multi-institutional
study in Korea conducted over 13 years that included
1064 cases of pathologically confirmed PCNs, showed
that the incidence of SPN was 18.3% in 2008 [24]. Sev-
eral large single-institution series on SPN have been re-
ported about in other Asian countries such as Singapore
[25], Taiwan [26], India [27], and Japan [28]. This appar-
ent increase in the incidence of SPNs in our study may
represent a true increase in incidence resulting from un-
known environmental or genetic factors in Asia. On the
other hand, there may be possible selection bias; since
we included cases of surgically resection only, the in-
crease in the SPN rate may be overestimated as most
other PCNs are managed by conservative treatment.
Surgical intervention generally depends on the loca-
tion and size of the tumor [13]. Tumors of the head and
uncinate process should be treated with pancreatoduo-
denectomy. Small lesions can also be managed with mid-
dle pancreatectomy or tumor enucleation, sparing the
pancreatic tissue. Distal pancreatectomy, with or without
spleen preservation, should be performed for PCNs
identified in the body and tail of the pancreas [29].
In our study, the mortality rate was 0.9%; that is, only
one patient died in the perioperative period as a result
of pulmonary infection. The overall complication rate
was 45.0%. These results are similar to those reported in
other literature [15,30]. The most common complication
was pancreatic fistula; its incidence was highest in the
patients who underwent middle pancreatectomy, but
there was no significant difference between these surgi-
cal treatments. Therefore, middle pancreatectomy is rec-
ommended in cases where major pancreatic resection,
such as pancreaticoduodenectomy, is not required
PCNs encompass a wide spectrum of benign, border-
line, and malignant diseases; the preoperative identifica-
tion of predictors for malignancy is very critical for
subsequent management. Following the primary assess-
ment of the clinical presentation, tumor markers and
imaging examinations are recommended for preoperative
evaluation. PCNs with elevated serum CEA or CA19-9
should be treated with surgical resection because of the
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sion [29]. Our statistical analyses confirmed that an ele-
vated CEA and/or CA19-9 is an independent predictive
factor for malignant pancreatic cysts (P = 0.011). In radio-
logical studies, mural nodules, symptoms associated with
the cyst, thick septa, peripheral calcification, and concomi-
tant dilation of the pancreatic duct are features associated
with malignancy [1]. CT and MRI scans are both capable
of predicting the presence of malignancy in pancreatic
cysts more accurately (73 to 79%) than other imaging
methods in use [31]. In China, EUS is much more com-
monly used to perform FNA in order to provide fluid for
cytological analysis and tumor markers or amylase testing,
which plays an important role in diagnosis of PCNs. Al-
though there was a marked increase in the use of EUS/
FNA, EUS alone has been shown to be inadequate for dif-
ferentiating neoplastic cysts from non-neoplastic cysts be-
cause of the considerable overlap between mucinous and
non-mucinous cysts [16,32].
From the follow-up data, the prognosis of patients
with resected PCNs seems to be favorable. None of our
SPN patients died during the study period, which is con-
sistent with the relatively indolent biological properties of
this tumor. For mucin-producing tumors, a significantly
lower survival rate was found in MCNs (90.0%) and IPMNs
(87.5%), consistent with the reports of others [4,15].
Conclusions
With the widespread use of high-resolution abdominal
imaging, the detection rate of PCNs has increased. How-
ever, there are still obstacles in the differential diagnosis
of various types of PCNs. In recent years, the mortality
rate and major complications have decreased with im-
provements in pancreatic surgery techniques and peri-
operative management. Favorable long-term survival
after resection of PCNs compared to adenocarcinoma
has also been obtained. Therefore, aggressive surgical re-
section is advocated for PCN patients, especially in the
case of those with symptoms, elevated CA19-9 or CEA
levels, and malignancy features.
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